Pfizer Sues Mylan To Block Generic Sutent

Law360, New York (June 17, 2010, 4:54 PM EDT) -- Pfizer Inc. has lodged a patent infringement suit in an effort to prevent Mylan Inc. from introducing a generic version of blockbuster cancer drug Sutent.

The drugmaker filed suit Wednesday in the U.S. District Court for the District of Delaware, alleging that Mylan Inc. and a subsidiary infringed three patents when they submitted an abbreviated new drug application with the U.S. Food and Drug Administration.

“Unless Mylan Inc. and Mylan Pharmaceuticals [Inc.] are enjoined from infringement of the [patents], from actively inducing infringement of the [patents]...
To view the full article, register now.